Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Paranjape

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Gut|October 17, 2009
MicroRNAs: tools for cancer diagnosticsT Paranjape, F J Slack, J B Weidhaas
Oncogene|May 8, 2009
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cellsM Kato, T Paranjape, R U Müller, et al.
Oncogene|June 10, 2014
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancerX Chen, T Paranjape, C Stahlhut, et al.
Oncogene|December 2, 2010
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaS E Godshalk, T Paranjape, S Nallur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2014
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinomaC H Chung, J W Lee, R J Slebos, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Gut|October 17, 2009
MicroRNAs: tools for cancer diagnosticsT Paranjape, F J Slack, J B Weidhaas
Oncogene|May 8, 2009
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cellsM Kato, T Paranjape, R U Müller, et al.
Oncogene|June 10, 2014
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancerX Chen, T Paranjape, C Stahlhut, et al.
Oncogene|December 2, 2010
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaS E Godshalk, T Paranjape, S Nallur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2014
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinomaC H Chung, J W Lee, R J Slebos, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 1